A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.
Christopher PleyerXin TianShakuntala RampertaapRui MuSusan SotoJeanine SuperataErika M GaglioneClare SunJennifer LotterMaryalice Stetler-StevensonConstance M YuanIrina MaricStefania PittalugaSergio RosenzweigThomas FleisherAdrian WiestnerInhye E AhnPublished in: American journal of hematology (2020)